The wire — 9 November 2026

Monday, 9 November — the week opens with no qualifying rounds confirmed in-window. News indexing typically lags 48-72 hours behind Monday announcements, and the European press cycle builds in earnest from Tuesday. Two rounds announced Wednesday 5 November that did not reach earlier editions are published today as standalone deal stories, each dated to its real announcement date. No single thread ties them: an Oxford oncology Series A and a Paris healthcare-AI seed belong to different sectors, stages, and investor bases — this is a catch-up day, not a thematic one.

Alethio Therapeutics raises $90M (€80.5M) Series A — Oxford, United Kingdom. Co-led by Sofinnova Partners and RA Capital Management, with Oxford Science Enterprises, Cancer Research Horizons, and the University of Oxford. The company, an Oxford spinout founded in 2024, is developing ATX-011 — a G6B-targeting antibody for essential thrombocythemia that acts independent of the JAK2, MPL, and CALR mutations that drive the disease. The round funds the transition to clinical-stage operation and IND filing for ATX-011. One of the larger European biotech Series A rounds of the season, led by two investors neither of whom had previously backed the company.

Granit raises €5M pre-seed — Paris, France. Led by Seedcamp (€3.5M equity), with Drysdale Ventures, Re:rail, Purple, Cleo Ventures, Kima Ventures, and a €1.5M non-dilutive Bpifrance grant. Founded March 2026 by Jenny Mansour and Corneille Maréchal, the company builds AI agents that log into existing healthcare software and insurer portals to handle billing, claims, and payment follow-ups for healthcare professionals — 250 organisations live in France within six months of launch.

Skipped this edition: Gallium Defense (Paris, €7.1M seed, counter-drone radar — primary military application, outside editorial scope); Shaarp (Paris, €400K pre-seed — insufficient corroboration of investor details); no rounds confirmed for today's window.